AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8932953 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymostimulin (TP1) for 10 days pre- and 6 months post-operatively
Number of subjects: 61
Study 8932953 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-TP1 treated patients)
Number of subjects: 61
Study 1447385 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine (CHX)
Number of subjects: 60
Study 1447385 — intervention group
Group type: COMPARATOR
Intervention: Sterile water
Number of subjects: 60
Study 3797487 — intervention group
Group type: EXPERIMENTAL
Intervention: Crystalline salt added to food for 4 weeks
Number of subjects: 3
Study 3797487 — intervention group
Group type: EXPERIMENTAL
Intervention: Salt tablets for 4 weeks
Number of subjects: 3
Study 3797487 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 3
Study 3797487 — intervention group
Group type: EXPERIMENTAL
Intervention: Crystalline salt added to food for 6 weeks
Number of subjects: 3
Study 3797487 — intervention group
Group type: EXPERIMENTAL
Intervention: Salt tablets for 6 weeks
Number of subjects: 3
Study 30874781 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate Intervention (II) group
Number of subjects: 324
Study 30874781 — intervention group
Group type: COMPARATOR
Intervention: Delayed Intervention (DI) group
Number of subjects: 324
Study 29378536 — intervention group
Group type: EXPERIMENTAL
Intervention: HeadCoach online training intervention for managers
Number of subjects: 168
Study 29378536 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 168
Study 27247178 — intervention group
Group type: EXPERIMENTAL
Intervention: Youths (ages 18 to 24)
Number of subjects: 164
Study 21989635 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive task specific training (RTP) for 6 weeks, approximately 2.5 hours per day, split into two sessions, with epidural cortical stimulation co-administered
Number of subjects: 5
Study 22835600 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 polyunsaturated fatty acids (PUFAs) administered at ≥2.7 g/day for a minimum duration of 3 months
Number of subjects: 370
Study 22835600 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 polyunsaturated fatty acids (PUFAs)
Number of subjects: 370
Study 22835600 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 370
Study 21047588 — intervention group
Group type: EXPERIMENTAL
Intervention: High grade PIN
Number of subjects: 56653
Study 21047588 — intervention group
Group type: EXPERIMENTAL
Intervention: LSPC
Number of subjects: 56653
Study 21047588 — intervention group
Group type: COMPARATOR
Intervention: Screening rounds 1, 2, and 3
Number of subjects: 56653
Study 17607078 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional agents such as active vitamin D3 and vitamin K2
Number of subjects: 0
Study 17607078 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-resorbers
Number of subjects: 0
Study 17607078 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D
Number of subjects: 0
Study 17607078 — intervention group
Group type: EXPERIMENTAL
Intervention: Extra-skeletal mechanisms of vitamin D
Number of subjects: 0
Study 15687102 — intervention group
Group type: EXPERIMENTAL
Intervention: Social-cognitive intervention with stage-targeted letters and interpersonal counseling
Number of subjects: 651
Study 15687102 — intervention group
Group type: EXPERIMENTAL
Intervention: Social-cognitive intervention
Number of subjects: 651
Study 15687102 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 651
Study 12006898 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide (75, 150, 300, 600, or 900 mg/day)
Number of subjects: 452
Study 12006898 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 452
Study 10096263 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-10 (8 microg/kg subcutaneous injection)
Number of subjects: 12
Study 10096263 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone (15 mg by mouth)
Number of subjects: 12
Study 10096263 — intervention group
Group type: COMPARATOR
Intervention: Placebo with prednisone
Number of subjects: 12
Study 10096263 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 10096263 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint effects of interleukin-10 and prednisolone
Number of subjects: 12
Study 10096263 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone
Number of subjects: 12
Study 10096263 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-10
Number of subjects: 12
Study 10096263 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic modeling
Number of subjects: 12
Study 8641320 — intervention group
Group type: EXPERIMENTAL
Intervention: Idrapril calcium (200 mg)
Number of subjects: 6
Study 8641320 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 2156913 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed Doppler ultrasound
Number of subjects: 8
Study 2156913 — intervention group
Group type: COMPARATOR
Intervention: Continuous wave Doppler ultrasonography
Number of subjects: 8
Study 6928104 — intervention group
Group type: EXPERIMENTAL
Intervention: Central nervous system prophylaxis (CNS‐P)
Number of subjects: 99
Study 6928104 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis (Control)
Number of subjects: 99
Study 6928104 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction regimen (vincristine plus low-dose methotrexate and high-dose prednisone)
Number of subjects: 99
Study 6928104 — intervention group
Group type: EXPERIMENTAL
Intervention: CNS‐P
Number of subjects: 99
Study 31714037 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized decision support intervention
Number of subjects: 57
Study 31138676 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-week online mindfulness-based intervention (MBI)
Number of subjects: 323
Study 31138676 — intervention group
Group type: COMPARATOR
Intervention: Control group (wait list)
Number of subjects: 323
Study 27967288 — intervention group
Group type: EXPERIMENTAL
Intervention: Kabat physical rehabilitation combined with steroid treatment
Number of subjects: 100
Study 27967288 — intervention group
Group type: COMPARATOR
Intervention: Steroid treatment alone
Number of subjects: 100
Study 26055847 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal hemoglobin concentration measured at first and second ANC visits and at delivery.
Number of subjects: 636
Study 26055847 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral iron, folic acid, and anthelminthics prescribed after the first ANC visit.
Number of subjects: 636
Study 24634110 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacosamide (200 mg twice daily)
Number of subjects: 20
Study 24634110 — intervention group
Group type: COMPARATOR
Intervention: Digoxin alone
Number of subjects: 20
Study 22607870 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin plus eptifibatide
Number of subjects: 91
Study 22607870 — intervention group
Group type: COMPARATOR
Intervention: Heparin alone
Number of subjects: 91
Study 20854987 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic product containing Lactobacillus gasseri CHO-220 and inulin
Number of subjects: 32
Study 20854987 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 17993025 — intervention group
Group type: EXPERIMENTAL
Intervention: Gutta‐percha with AH 26
Number of subjects: 70
Study 17993025 — intervention group
Group type: EXPERIMENTAL
Intervention: Gutta‐percha with AH Plus
Number of subjects: 70
Study 17993025 — intervention group
Group type: EXPERIMENTAL
Intervention: Resilon with Epiphany
Number of subjects: 70
Study 15331966 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporal lobectomy for drug-resistant temporo-mesial epilepsy
Number of subjects: 0
Study 15331966 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemispherotomy
Number of subjects: 0
Study 15331966 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic radiosurgery
Number of subjects: 0
Study 15331966 — intervention group
Group type: EXPERIMENTAL
Intervention: Callosotomy
Number of subjects: 0
Study 15331966 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple subpial transection
Number of subjects: 0
Study 15331966 — intervention group
Group type: EXPERIMENTAL
Intervention: Resective surgery
Number of subjects: 0
Study 15331966 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative complications
Number of subjects: 0
Study 11960925 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal exercise test on a treadmill
Number of subjects: 12
Study 9794345 — intervention group
Group type: EXPERIMENTAL
Intervention: Precordial actual TENS
Number of subjects: 18
Study 9794345 — intervention group
Group type: COMPARATOR
Intervention: Simulated TENS and TENS on the back
Number of subjects: 18
Study 9794345 — intervention group
Group type: COMPARATOR
Intervention: TENS (all patients)
Number of subjects: 18
Study 7623389 — intervention group
Group type: EXPERIMENTAL
Intervention: Matrix outpatient model
Number of subjects: 0
Study 2651493 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem 5.0 mg and larger doses
Number of subjects: 12
Study 2651493 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem 7.5 mg and higher doses
Number of subjects: 12
Study 2651493 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem 20 mg
Number of subjects: 12
Study 2651493 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 7468415 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing carbon monoxide (CO) raising COHb from 1.09% to 2.02%
Number of subjects: 15
Study 7468415 — intervention group
Group type: COMPARATOR
Intervention: Breathing compressed, purified air lowering COHb from 1.07% to 1.00%
Number of subjects: 15
Study 31100125 — intervention group
Group type: EXPERIMENTAL
Intervention: Reformed national school feeding program providing 1 hot meal/day in public primary schools
Number of subjects: 2869
Study 31100125 — intervention group
Group type: COMPARATOR
Intervention: Control group without intervention
Number of subjects: 2869
Study 28573779 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily application of skincare (Normaderm®) with fixed combination of adapalene/benzoyl peroxide
Number of subjects: 299
Study 28573779 — intervention group
Group type: COMPARATOR
Intervention: Standard emollient alone with fixed combination of adapalene/benzoyl peroxide
Number of subjects: 299
Study 26399575 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual primary care with the addition of an internet intervention
Number of subjects: 0
Study 26399575 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet intervention with physiotherapist telephone support
Number of subjects: 0
Study 26399575 — intervention group
Group type: COMPARATOR
Intervention: Usual primary care
Number of subjects: 0
Study 23356386 — intervention group
Group type: EXPERIMENTAL
Intervention: MBL-HCV1 (50 mg/kg, 11 infusions)
Number of subjects: 11
Study 23356386 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 21304020 — intervention group
Group type: EXPERIMENTAL
Intervention: FET + COT (n = 9)
Number of subjects: 24
Study 21304020 — intervention group
Group type: COMPARATOR
Intervention: COT (n = 12)
Number of subjects: 24
Study 19746439 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukotriene receptor antagonists (LTRAs) in addition to fexofenadine (FEX) for 16 weeks
Number of subjects: 44
Study 19746439 — intervention group
Group type: EXPERIMENTAL
Intervention: Acoustic rhinometry at 16 weeks
Number of subjects: 44
Study 19746439 — intervention group
Group type: COMPARATOR
Intervention: Placebo in addition to fexofenadine (FEX) for 16 weeks
Number of subjects: 44
Study 18547587 — intervention group
Group type: EXPERIMENTAL
Intervention: Social anxiety at baseline
Number of subjects: 404
Study 18547587 — intervention group
Group type: EXPERIMENTAL
Intervention: Observation anxieties
Number of subjects: 404
Study 18547587 — intervention group
Group type: EXPERIMENTAL
Intervention: Social interaction anxiety
Number of subjects: 404
Study 18547587 — intervention group
Group type: COMPARATOR
Intervention: Controlling for gender, depression, trait anxiety
Number of subjects: 404
Study 15345796 — intervention group
Group type: EXPERIMENTAL
Intervention: t‐PA therapy
Number of subjects: 0
Study 15345796 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11774075 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ribavirin treatment
Number of subjects: 140
Study 9015579 — intervention group
Group type: EXPERIMENTAL
Intervention: Yohimbine (up to 30 mg/day)
Number of subjects: 11
Study 8235862 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation over the lower lumbar paraspinal muscles for 30 minutes twice a day.
Number of subjects: 40
Study 8235862 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified what the control was).
Number of subjects: 40
Study 3469601 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcoholic benzydamine hydrochloride
Number of subjects: 18
Study 3469601 — intervention group
Group type: EXPERIMENTAL
Intervention: Aqueous chlorhexidine
Number of subjects: 18
Study 3469601 — intervention group
Group type: COMPARATOR
Intervention: Benzydamine-free placebo mouthwash
Number of subjects: 18
Study 11237234 — intervention group
Group type: EXPERIMENTAL
Intervention: MDI with home-made spacer (10 puffs of salbutamol, 100 microg/puff)
Number of subjects: 60
Study 11237234 — intervention group
Group type: COMPARATOR
Intervention: MDI with commercial spacer (10 puffs of salbutamol, 100 microg/puff)
Number of subjects: 60
Study 31331352 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterolateral approach
Number of subjects: 26
Study 31331352 — intervention group
Group type: COMPARATOR
Intervention: Lateral approach
Number of subjects: 26
Study 28643069 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic HIPEC with Mitomycin C 30 mg and Cisplatin 200 mg in 3-7 L of infusate for 60 min, performed up to five times.
Number of subjects: 19
Study 26778759 — intervention group
Group type: EXPERIMENTAL
Intervention: E-cigarette with 23.5% alcohol
Number of subjects: 0
Study 26778759 — intervention group
Group type: EXPERIMENTAL
Intervention: E-cigarette with 0.4% alcohol (trace)
Number of subjects: 0
Study 25453458 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent Pneumatic Compression (IPC)
Number of subjects: 2876
Study 22678178 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional, uncrossed manipulation system (UCMS) with straight instruments
Number of subjects: 18
Study 22678178 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional, uncrossed manipulation system (UCMS) with curved instruments
Number of subjects: 18
Study 22678178 — intervention group
Group type: COMPARATOR
Intervention: Crossed manipulation system (CMS) with curved instruments
Number of subjects: 18
Study 19942485 — intervention group
Group type: EXPERIMENTAL
Intervention: ALV003 pre-treated gluten (16 g daily for 3 days)
Number of subjects: 20
Study 19942485 — intervention group
Group type: COMPARATOR
Intervention: Placebo pre-treated gluten (16 g daily for 3 days)
Number of subjects: 20
Study 19942485 — intervention group
Group type: EXPERIMENTAL
Intervention: ALV003 pre-treated gluten
Number of subjects: 20
Study 19942485 — intervention group
Group type: COMPARATOR
Intervention: Placebo pre-treated gluten
Number of subjects: 20
Study 17511533 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive treatment group (n=16)
Number of subjects: 42
Study 17511533 — intervention group
Group type: COMPARATOR
Intervention: Control treatment group (n=26)
Number of subjects: 42
Study 16108935 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense tai chi exercise program
Number of subjects: 311
Study 16108935 — intervention group
Group type: COMPARATOR
Intervention: Wellness education (WE) program
Number of subjects: 311
Study 11953285 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy (Group B)
Number of subjects: 146
Study 11953285 — intervention group
Group type: COMPARATOR
Intervention: Conventional procedure (Group A)
Number of subjects: 146
Study 10364647 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrine 30 mg/day for 6 weeks, 60 mg/day for 6 weeks, 90 mg/day for 6 weeks, 120 mg/day for 12 weeks
Number of subjects: 100
Study 10364647 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrine (active group)
Number of subjects: 100
Study 10364647 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 100
Study 7562109 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 micrograms/d of total folate
Number of subjects: 17
Study 7562109 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 micrograms/d of total folate
Number of subjects: 17
Study 7562109 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 micrograms/d of total folate
Number of subjects: 17
Study 2389073 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.2% isoflurane (group A)
Number of subjects: 13
Study 2389073 — intervention group
Group type: COMPARATOR
Intervention: Control group (group B)
Number of subjects: 13
Study 6906160 — intervention group
Group type: EXPERIMENTAL
Intervention: timolol (0.1%) and dipivalyl-epinephrine (0.25%)
Number of subjects: 27
Study 6906160 — intervention group
Group type: EXPERIMENTAL
Intervention: timolol (0.25%) and dipivalyl-epinephrine (0.1%)
Number of subjects: 27
Study 6906160 — intervention group
Group type: COMPARATOR
Intervention: timolol (0.25%) bis x
Number of subjects: 27
Study 31265113 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary lysine level of 6.4 g/kg
Number of subjects: 540
Study 31265113 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary lysine level of 7.2 g/kg
Number of subjects: 540
Study 31265113 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary lysine level of 8.0 g/kg
Number of subjects: 540
Study 31265113 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary lysine level of 8.8 g/kg
Number of subjects: 540
Study 31265113 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary lysine level of 9.6 g/kg
Number of subjects: 540
Study 31265113 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary lysine level of 10.4 g/kg
Number of subjects: 540
Study 31265113 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary lysine level of 8.6 g/kg
Number of subjects: 540
Study 27400922 — intervention group
Group type: EXPERIMENTAL
Intervention: Case Management (CM) intervention consisting of assistance in obtaining income entitlements, referral to primary or specialty medical care, access to mental health care or substance abuse treatment, and counseling on at-risk behaviors and health care utilization.
Number of subjects: 250
Study 27400922 — intervention group
Group type: COMPARATOR
Intervention: Standard emergency care (control group).
Number of subjects: 250
Study 27400922 — intervention group
Group type: EXPERIMENTAL
Intervention: Case Management (CM) intervention.
Number of subjects: 250
Study 27400922 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor social determinants of health (predictor variable).
Number of subjects: 250
Study 24326412 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal medicine/endocrinology practice
Number of subjects: 168
Study 24326412 — intervention group
Group type: COMPARATOR
Intervention: Family practice clinic
Number of subjects: 168
Study 24705855 — intervention group
Group type: EXPERIMENTAL
Intervention: E‐MOSAIC (PALM version)
Number of subjects: 62
Study 24705855 — intervention group
Group type: COMPARATOR
Intervention: E‐MOSAIC (paper version)
Number of subjects: 62
Study 23265031 — intervention group
Group type: EXPERIMENTAL
Intervention: Analgesia with remifentanil
Number of subjects: 58
Study 23265031 — intervention group
Group type: COMPARATOR
Intervention: Anesthesia with propofol and alfentanil
Number of subjects: 58
Study 19544097 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefditoren
Number of subjects: 4582
Study 19544097 — intervention group
Group type: COMPARATOR
Intervention: Comparators
Number of subjects: 4582
Study 17726084 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine
Number of subjects: 50
Study 17726084 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 15831772 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (inhaled corticosteroids, 2 mg)
Number of subjects: 18
Study 15831772 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisolone (oral corticosteroids, 50 mg)
Number of subjects: 18
Study 15831772 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 18
Study 11691516 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogen, 0.625 mg/day for 8 weeks
Number of subjects: 20
Study 11691516 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 10205349 — intervention group
Group type: EXPERIMENTAL
Intervention: gamma-linolenic and eicosapentaenoic acids
Number of subjects: 120
Study 10205349 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 120
Study 7933039 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous wave Doppler examination
Number of subjects: 42
Study 7933039 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard duplex scanning
Number of subjects: 42
Study 7933039 — intervention group
Group type: EXPERIMENTAL
Intervention: Color Doppler flow imaging
Number of subjects: 42
Study 7933039 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic methods (continuous wave Doppler combined with color Doppler flow imaging)
Number of subjects: 42
Study 3280614 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilazep (0.2 mg/kg body weight by IV infusion for ten minutes)
Number of subjects: 12
Study 31720819 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin or cilostazol treatment with best medical therapy
Number of subjects: 1240
Study 29318443 — intervention group
Group type: EXPERIMENTAL
Intervention: Push intervention components of mHealth interventions (e.g., notifications or text messages)
Number of subjects: 0
Study 29318443 — intervention group
Group type: EXPERIMENTAL
Intervention: HeartSteps mHealth intervention
Number of subjects: 0
Study 29165753 — intervention group
Group type: COMPARATOR
Intervention: Intravenous injection of 0.5 μg/kg remifentanil (Control group)
Number of subjects: 46
Study 29165753 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomization inhalation of 15 mg ambroxol hydrochloride and 0.5 mg budesonide suspension (Observation group)
Number of subjects: 46
Study 25831405 — intervention group
Group type: EXPERIMENTAL
Intervention: H2N2 live attenuated influenza vaccine (LAIV)
Number of subjects: 0